Glucocorticoid status affects antidepressant regulation of locus coeruleus tyrosine hydroxylase and dorsal raphé tryptophan hydroxylase gene expression

Brain Research

Volumn 1288, Issue , 2009, Pages 69-78

  Heydendael, Willem ^a   Jacobson, Lauren ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Glucocorticoid; Glucocorticoid receptor; HPA axis; Mineralocorticoid receptor; Monoamine oxidase inhibitor; Norepinephrine; Serotonin; Tricyclic antidepressant

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOSTERONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMIPRAMINE; MINERALOCORTICOID RECEPTOR; NORADRENALIN; PHENELZINE; SEROTONIN; TRYPTOPHAN HYDROXYLASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG MECHANISM; GENE EXPRESSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IN SITU HYBRIDIZATION; LOCUS CERULEUS; MALE; MONOAMINE METABOLISM; MOOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; VENTRAL TEGMENTUM;

ADRENALECTOMY; ADRENERGIC UPTAKE INHIBITORS; ANALYSIS OF VARIANCE; ANIMALS; CORTICOSTERONE; GENE EXPRESSION; IMAGE PROCESSING, COMPUTER-ASSISTED; IMIPRAMINE; IN SITU HYBRIDIZATION; LOCUS COERULEUS; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; PHENELZINE; RAPHE NUCLEI; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; TRYPTOPHAN HYDROXYLASE; TYROSINE 3-MONOOXYGENASE; UP-REGULATION; VENTRAL TEGMENTAL AREA;

MUS;

EID: 69049095900     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.06.082     Document Type: Article

References (66)

1. Aman T.K., Shen R.-Y., and Haj-Dahmane S. D2-like dopamine receptors depolarize dorsal raphé serotonin neurons through the activation of nonselective cationic conductance. J. Pharmacol. Exp. Ther. 320 (2007) 376-385
2. American Psychiatric Association. In: A.P. Association (Ed). Diagnostic and Statistical Manual of Mental Disorders IV. Vol (2000), American Psychiatric Association, Washington, D. C. 419-422
3. Anisman H., Ravindran A.V., Griffiths J., and Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry 4 (1999) 182-188
4. Antakly T., Mercille S., and Côté J. Tissue-specific dopaminergic regulation of the glucocorticoid receptor in the rat pituitary. Endocrinology 120 (1987) 1558-1562
5. Aronsson M., Fuxe K., Dong Y., Agnati L.F., Okret S., and Gustafsson J.A. Localization of glucocorticoid receptor mRNA in the male rat brain by in situ hybridization. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 9331-9335
6. Arriza J.L., Simerly R.B., Swanson L.W., and Evans R.M. The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron 1 (1988) 887-900
7. Bach-Mizrachi H., Underwood M.D., Kassir S.A., Bakalian M.J., Sibille E., Tamir H., Mann J.J., and Arango V. Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphé nuclei: major depression and suicide. Neuropsychopharmacology 31 (2006) 814-824
8. Baldessarini R.J. Drug therapy of depression and anxiety disorders. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. Vol. (2006), McGraw-Hill, New York 429-459
9. Brady L.S., Whitfield Jr. H.J., Fox R.J., Gold P.W., and Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J. Clin. Invest. 87 (1991) 831-837
10. Brady L.S., Gold P.W., Herkenham M., Lynn A.B., and Whitfield Jr. H.J. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res. 572 (1992) 117-125
11. Casolini P., Piazza P.V., Kabbaj M., Leprat F., Angelucci L., Simon H., Moal M.L., and Maccari S. The mesolimbic dopaminergic system exerts an inhibitory influence on brain corticosteroid receptor affinities. Neuroscience 55 (1993) 429-434
12. Castonguay T.W., Beaulieu S.S., Eskay R.L., Barden N., Kamara K., Khozin S., Lustberg L., and Brown L. The effects of adrenalectomy and aldosterone replacement in transgenic mice expressing antisense RNA to the type 2 glucocorticoid receptor. Physiol. Behav. 77 (2002) 417-423
13. Clark J.A., Flick R.B., Pai L.Y., Szalayova I., Key S., Conley R.K., Deutch A.Y., Hutson P.H., and Mezey E. Glucocorticoid modulation of tryptophan hydroxylase-2 protein in raphé nuclei and 5-hydroxytryptophan concentrations in frontal cortex of C57/Bl6 mice. Mol. Psychiatry 13 (2008) 498-506
14. Clark M.S., and Russo A.F. Tissue-specific glucocorticoid regulation of tryptophan hydroxylase mRNA levels. Brain Res.: Mol. Brain Res. 48 (1997) 346-354
15. Clayton P.J. Depression subtyping: treatment implications. J. Clin. Psychiatry 59 (1998) 5-12 discussion 40-2
16. Czyrak A., and Chocyk A. Search for the presence of glucocorticoid receptors in dopaminergic neurons of rat ventral tegmental area and substantia nigra. Pol. J. Pharmacol. 53 (2001) 681-684
17. Delgado P.L. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J. Clin. Psychiatry 67 suppl 4 (2006) 22-26
18. Drevets W.C., Bogers W., and Raichle M.E. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur. Neuropsychopharmacol. 12 (2002) 527-544
19. Duncan G.E., Knapp D.J., Johnson K., and Breese G.R. Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 277 (1996) 1076-1089
20. Gold P.W., Gabry K.E., Yasuda M., and Chrousos G.P. Divergent endocrine abnormalities in melancholic and atypical depression: clinical and pathophysiological implications. Endocrinol. Metab. Clin. N. Am. 31 (2002) 37-62
21. Griebel G., Curet O., Perrault G., and Sanger D.J. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology 37 (1998) 927-935
22. Guiard B.P., Mansari M.E., and Blier P. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus coeruleus, and dorsal hippocampus. Mol. Pharmacol. 74 (2008) 1463-1475
23. Harfstrand A., Fuxe K., Cintra A., Agnanti L.F., Zini I., Wikstrom A.C., Okret S., Yu Z.Y., Goldstein M., Steinbusch H., et al. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 9779-9783
24. Harro J., and Oreland L. Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Res. Rev. 38 (2001) 79-128
25. Hasler G., Fromm S., Carlson P., Luckenbaugh D., Waldeck T., Geraci M., Roiser J., Neumeister A., Meyers N., Charney D., and Drevets W. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch. Gen. Psychiatry 65 (2008) 521-531
26. Hatzinger M., Hemmeter U.M., Baumann K., Brand S., and Holsboer-Trachsler E. The combined DEX-CRH test in treatment course and long-term outcome of major depression. J. Psychiatr. Res. 36 (2002) 287-297
27. Herman J.P. Regulation of adrenocorticosteroid receptor mRNA expression in the central nervous system. Cell. Molec. Neurobiol. 13 (1993) 349-372
28. Herman J.P., Figueiredo H., Mueller N.K., Ulrich-Lai Y., Ostrander M.M., Choi D.C., and Cullinan W.E. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front. Neuroendocrinol. 24 (2003) 151-180
29. Heuser I., Yassouridis A., and Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J. Psychiatr. Res. 28 (1994) 341-356
30. Heydendael W., and Jacobson L. Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response. Brain Res. (2008) 93-107
31. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J. Affect. Disord. 62 (2001) 77-91
32. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals (1996), National Academy Press, Washington, DC
33. Jay T.M. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Progr. Neurobiol. 69 (2003) 375-390
34. Jeong K.H., Jacobson L., Pacak K., Widmaier E.P., Goldstein D.S., and Majzoub J.A. Impaired basal and restraint-induced epinephrine secretion in corticotropin-releasing hormone-deficient mice. Endocrinology 141 (2000) 1142-1150
35. Kier A., Han J., and Jacobson L. Chronic treatment with the monoamine oxidase inhibitor phenelzine increases hypothalamic-pituitary-adrenocortical activity in male C57BL/6 mice: relevance to atypical depression. Endocrinology 146 (2005) 1338-1347
36. Lechner S.M., and Valentino R.J. Glucocorticoid receptor-immunoreactivity in corticotrophin-releasing factor afferents to the locus coeruleus. Brain Res. 816 (1999) 17-28
37. Levitan R.D., Vaccarino F.J., Brown G.M., and Kennedy S.H. Low-dose dexamethasone challenge in women with atypical major depression: pilot study. J. Psychiatry Neurosci. 27 (2002) 47-51
38. Liggett S.B. Genetically modified mouse models for pharmacogenomic research. Nat. Rev. Genet. 5 (2004) 657-663
39. Lin J.K. Applications and limitations of genetically modified mouse models in drug discovery and development. Curr. Drug Metab. 9 (2008) 419-438
40. Loughlin S.E., Foote S.L., and Grzanna R. Efferent projections of nucleus locus coeruleus: morphologic subpopulations have different efferent targets. Neuroscience 18 (1986) 307-319
41. Lowry C. Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis. J. Neuroendocrinol. 14 (2002) 911-923
42. Lucki I., Dalvi A., and Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155 (2001) 315-322
43. Makino S., Smith M.A., and Gold P.W. Regulatory role of glucocorticoids and glucocorticoid receptor mRNA levels on tyrosine hydroxylase gene expression in the locus coeruleus during repeated immobilization stress. Brain Res. 943 (2002) 216-223
44. Marcus S.M., Kerber K.B., Rush A.J., Wisniewski S.R., Nierenberg A., Balasubramani G.K., Ritz L., Kornstein S., Young E.A., and Trivedi M.H. Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Compr. Psychiatry 49 (2008) 238-246
45. McGrath P.S., Stewart J.W., Petkova E., Quitkin F.M., Amsterdam J.D., Fawcett J., Reimherr F.W., Rosenbaum Jr. J.F., and C. M. B. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J. Clin. Psychiatry 61 (2000) 518-524
46. Mizoguchi K., Shoji H., Ikeda R., Tanaka Y., and Tabira T. Persistent depressive state after chronic stress in rats is accompanied by HPA axis dysregulation and reduced prefrontal dopaminergic neurotransmission. Pharmacol., Biochem. Behav. 91 (2008) 170-175
47. Mongeau R., Blier P., and DeMontigny C. The serotonergic and noradreneric systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res. Rev. 23 (1997) 145-195
48. Moore R.Y., Halaris A.E., and Jones B.E. Serotonin neurons of the midbrain raphé: ascending projections. J. Comp. Neurol. 180 (1978) 417-438
49. Mukherjee K., Knisely A., and Jacobson L. Partial glucocorticoid agonist-like effects of imipramine on hypothalamic-pituitary-adrenocortical activity, thymus weight, and hippocampal glucocorticoid receptors in male C57BL/6 mice. Endocrinology 145 (2004) 4185-4191
50. Nestler E.J., McMahon A., Sabban E.L., Tallman J.F., and Duman R.S. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 7522-7526
51. Nutt D. The neuropharmacology of serotonin and noradrenaline in depression. Int. Clin. Psychopharmacol. 17 (2002) 1-12
52. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 (2001) 391-404
53. Paxinos G., and Franklin K. The Mouse Brain in Stereotaxic Coordinates, 2nd ed (2001), Academic Press, San Diego, CA USA
54. Posener J.A., DeBattista C., Williams G.H., Chmura Kraemer H., Kalehzan B.M., and Schatzberg A.F. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch. Gen. Psychiatry 57 (2000) 755-760
55. Reul J.M., and de Kloet E.R. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117 (1985) 2505-2511
56. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry 57 (2000) 925-935
57. Shishkina G.T., Kalinina T.S., and Dygalo D.N. Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect. Neuroscience 150 (2007) 404-412
58. Sirois F. Steroid psychosis: a review. Gen. Hosp. Psychiatry 25 (2003) 27-33
59. Smith M.A., Brady L.S., Glowa J., Gold P.W., and Herkenham M. Effects of stress and adrenalectomy on tyrosine hydroxylase mRNA levels in the locus coeruleus by in situ hybridization. Brain Res. 544 (1991) 26-32
60. Stewart J.W., Quitkin F.M., McGrath P.J., and Klein D.F. Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions. J. Affective Disord. 86 (2005) 161-167
61. Swanson L.W. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res. Bull. 9 (1982) 321-353
62. Tenner K., Qadri F., Bert B., Voigt J.P., and Bader M. The mTPH2 C1473G single nucleotide polymorphism is not responsible for behavioural differences between mouse strains. Neurosci. Lett. 431 (2008) 21-25
63. Thase M.E., Trivedi M.H., and Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12 (1995) 185-219
64. Walther D.J., and Bader M. A unique central tryptophan hydroxylase isoform. Biochem. Pharmacol. 66 (2003) 1673-1680
65. Wong M.L., Kling M.A., Munson P.J., Listwak S., Licinio J., Prolo P., Karp B., McCutcheon I.E., Geracioti Jr. T.D., DeBellis M.D., Rice K.C., Goldstein D.S., Veldhuis J.D., Chrousos G.P., Oldfield E.H., McCann S.M., and Gold P.W. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 325-330
66. Ziegler D.R., Cass W.A., and Herman J.P. Excitatory influence of the locus coeruleus in hypothalamic-pituitary-adrenocortical axis responses to stress. J. Neuroendocrinol. 11 (1999) 361-369